CJC-1295 (no DAC) Research: What 36 Studies Show (2026) | RetatrutideCompare

CJC-1295 (no DAC) — 36 studies indexed on PubMed. Stabilized GHRH analog without the drug affinity complex (DAC). Drives a clean GH pulse without the days-long elevation. Half-life: ~30 minutes. FDA status: Not FDA-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on CJC-1295 (no DAC)?

There are approximately 36 studies indexed on PubMed that mention CJC-1295 (no DAC) (Mod GRF 1-29, Modified GRF), based on a search last updated 2026-06-18.

Is CJC-1295 (no DAC) FDA-approved?

FDA status: Not FDA-approved.

How does CJC-1295 (no DAC) work?

Stabilized GHRH analog without the drug affinity complex (DAC). Drives a clean GH pulse without the days-long elevation.

Reference facts

Also known as: Mod GRF 1-29, Modified GRF
Category: Growth Hormone & Ghrelin
Mechanism of action: Stabilized GHRH analog without the drug affinity complex (DAC). Drives a clean GH pulse without the days-long elevation.
Targets: GHRHR
Indications under research or approved: Off-label research (adult GH support)
Regulatory status (reference entry): Not FDA-approved
Half-life: ~30 minutes
Sequence: YADAIFTNSYRKVLGQLSARKLLQDIMSR
Sequence notes: Tetrasubstituted Sermorelin: D-Ala²,Gln⁸,Ala¹⁵,Leu²⁷. The four substitutions resist DPP-4 cleavage and asparagine rearrangement.
Molecular weight (Da): 3367
Originator / sponsor: Originally ConjuChem (research)
First reported: 2005

Primary References

Teichman et al., JCEM 2006 (CJC-1295 PK)

Explore research articles about CJC-1295 (no DAC)

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.